- Home
- PRSO vs NCNA Comparison
PRSO vs NCNA Comparison
Compare PRSO & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRSO
- NCNA
- Stock Information
- Founded
- PRSO 2008
- NCNA 1997
- Country
- PRSO United States
- NCNA United Kingdom
- Employees
- PRSO N/A
- NCNA N/A
- Industry
- PRSO Semiconductors
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- PRSO Technology
- NCNA Health Care
- Exchange
- PRSO Nasdaq
- NCNA Nasdaq
- Market Cap
- PRSO 4.2M
- NCNA 4.4M
- IPO Year
- PRSO 2001
- NCNA 2017
- Fundamental
- Price
- PRSO $1.04
- NCNA $1.29
- Analyst Decision
- PRSO Strong Buy
- NCNA Buy
- Analyst Count
- PRSO 2
- NCNA 2
- Target Price
- PRSO $3.38
- NCNA $25.00
- AVG Volume (30 Days)
- PRSO 125.2K
- NCNA 99.0K
- Earning Date
- PRSO 11-12-2024
- NCNA 11-25-2024
- Dividend Yield
- PRSO N/A
- NCNA N/A
- EPS Growth
- PRSO N/A
- NCNA N/A
- EPS
- PRSO N/A
- NCNA N/A
- Revenue
- PRSO $12,728,000.00
- NCNA N/A
- Revenue This Year
- PRSO $9.59
- NCNA N/A
- Revenue Next Year
- PRSO $1.63
- NCNA N/A
- P/E Ratio
- PRSO N/A
- NCNA N/A
- Revenue Growth
- PRSO N/A
- NCNA N/A
- 52 Week Low
- PRSO $0.73
- NCNA $1.20
- 52 Week High
- PRSO $11.20
- NCNA $19.40
- Technical
- Relative Strength Index (RSI)
- PRSO 55.90
- NCNA 38.62
- Support Level
- PRSO $0.80
- NCNA $1.23
- Resistance Level
- PRSO $1.12
- NCNA $1.39
- Average True Range (ATR)
- PRSO 0.09
- NCNA 0.06
- MACD
- PRSO 0.05
- NCNA 0.03
- Stochastic Oscillator
- PRSO 88.69
- NCNA 37.05
About PRSO Peraso Inc.
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.